BMY Q3 2018 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$121B

Q3 2018 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$5.7B+8.3% YoY

Gross Profit

$4.0B71.0% margin

Operating Income

$1.7B29.5% margin

Net Income

$1.9B33.4% margin

EPS (Diluted)

$1.16

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$1.1B

Stock-Based Comp.

$62M

Balance Sheet

Total Assets

$33.7B

Total Liabilities

$20.0B

Stockholders' Equity

$13.6B

Cash & Equivalents

$5.4B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.7B	$5.3B	+8.3%
Gross Profit	$4.0B	$3.7B	+9.5%
Operating Income	$1.7B	$1.1B	+57.6%
Net Income	$1.9B	$845M	+125.0%

Revenue Segments

Opdivo

$1.8B31%

Eliquis

$1.6B28%

Orencia

$675M12%

Sprycel

$491M9%

Yervoy

$382M7%

Other Legacy Brands

$382M7%

Baraclude

$175M3%

Reyataz

$87M2%

Sustiva Franchise

$72M1%

Empliciti

$59M1%

Geographic Segments

UNITED STATES

$3.2B57%

Europe

$1.4B24%

Rest Of World

$932M16%

Other Region

$159M3%